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Abstract Candida infections are often associated
with biofilms and consequent high resistance to most
common drugs (e.g. azoles). These resistance mech-
anisms are not only associated with the biofilm yeast
physiology, but also with the presence of a diffusional
barrier imposed by the biofilm matrix; however, the
real biochemical role of the biofilm components
remains very unclear. So, in order to further clarify
this issue, we intend to determine, for the first time,
fluconazole in biofilms within both supernatants and
matrices. Candida biofilms were formed in the
presence of fluconazole, and it was recovered from
both supernatant and matrix cell-free fractions. Then,
high-pressure liquid chromatography was used to
identify and quantify the amount of drug that was
present in the two fractions. Moreover, this study also
showed that the presence of fluconazole in both
fractions indicated that the drug administrated did not
completely reach the cells, so this phenomena can
easily be associated with lower biofilm susceptibility,
since the drug administered did not completely reach
the cells.
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Introduction
The incidence of fungal infections has increased
meaningfully in the last decades, especially in immu-
nosuppressed and/or hospitalized patients, causing
high levels of morbidity and mortality [1]. The rise in
antimicrobial resistance and the restricted number of
effective antifungal drugs, which still have many side
effects, may be responsible for this event, specially
related to infections caused by yeasts from the
Candida genus [2]. In fact, Candida species are the
third most common cause of nosocomial infections
and the most common etiologic agent of fungal-related
biofilm infections [3, 4]. Between the Candida
species, Candida glabrata is the second most
prevalent pathogenic fungal species in humans, after
Candida albicans [2]. Even though C. glabrata is not
capable of producing hyphae, it has a number of
virulent factors, comprising secretion of hydrolytic
enzymes, adhesion to host cells or to medical devices,
and biofilm formation [3]. This last and very important
capability can occur on the host mucosa and on the
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medical indwelling surfaces devices, and it involves
the production of an extracellular matrix that encloses
yeasts’ microcolonies [4]. Biofilms are biological
communities with an extraordinary degree of organi-
zation, in which microorganisms form structured,
coordinated, and functional communities, embedded
in a self-created extracellular matrix. Biofilm produc-
tion is also associated with a high level of antifungal
resistance. The ability of Candida species to form
drug-resistant biofilm is an important factor in their
contribution to human disease [5–7]. In the widely
held view of microbial biofilms, sessile cells within
biofilms are less susceptible to antimicrobial agents
than planktonic cells, since the development of drug
resistance has been linked with an increase in the
maturation process [8, 9]. Additionally, many authors
have questioned whether biofilm matrices interfere in
its resistance. Still, it is difficult to overcome this
problem, since there is a lack of methodologies which
allow the detection of the amount of xenobiotics able
to diffuse into matrix and reach biofilm cells.
High-pressure liquid chromatography (HPLC) is a
very sensitive technique used to separate, identify, and
quantify the components in a mixture, and it is very
useful in biomedical assays. Reverse-phase HPLC
(RP-HPLC) is a particular model of HPLC which
operates on the principle of hydrophobic interactions,
allowing the measurement of these interactive forces
[10]. As several drugs were already identified and
quantified using this procedure [11], this methodology
was used to detect fluconazole.
Thus, the present work proposes an adapted meth-
odology for the detection and quantification of an
antifungal agent (fluconazole) in the biofilm environ-
ment, by HPLC, in order to understand its diffusion
within the matrix and to contribute to a better
understanding of biofilms’ tolerance to antifungal
agent phenomena.
Methods
Candida Biofilm Formation
Fluconazole (Flu) was kindly provided by Pfizer, S.A.,
in its pure compound. Aliquots with a final concen-
tration of 1,000 mg/L were prepared in dimethyl
sulfoxide and the final dilutions in Sabouraud dextrose
broth medium (SDB) (Merck, Darmstadt, Germany).
To validate the method, two strains of C. glabrata
(534784 and 562123 from the Hospital of Braga,
Portugal) were used. The identification of all isolates
strains was confirmed using CHROMagar Candida
(CHROMagar, Paris, France) and by PCR-based
sequencing using specific primers (ITS1 and ITS4)
against the 5.8-s subunit gene [10]. The PCR products
were sequenced using the ABI-PRISM Big Dye termi-
nator cycle sequencing kit (Perkin Elmer, Applied
Biosystems, Warrington, UK). C. glabrata strains were
subcultured on Sabouraud dextrose agar (SDA) (Merck,
Darmstadt, Germany) for 24 h at 37 C. Cells were then
inoculated in SDB (Merck, Darmstadt, Germany) and
incubated for 18 h at 37 C under agitation at 120 rev/
min. After incubation, the cells were harvested by
centrifugation at 3,000g for 10 min at 4 C and washed
twice with phosphate-buffered saline (PBS 0.1 M,
pH = 7.2). Pellets were then suspended in SDB, and
the cellular density was adjusted to 1 9 105 cells/mL
using a Neubauer counting chamber. Standardized cell
suspensions (500 lL) were placed into selected wells of
24-well polystyrene microtiter plates (Orange Scientific,
Braine-l‘Alleud, Belgium). As negative control, SDB
was used without cells and antifungal agent. As positive
control, only cell suspensions were tested without
antifungal agent. At 24 h, 250 lL of cell suspension
was removed and an equal volume of fresh SDB plus
250 lL of Flu (1,000 mg/L, 29 concentrated) were
added. The plateswere incubated at 37 C formore 24 h,
a total of 48 h at 120 rpm/min. After the biofilm
formation, the medium was aspirated and non-adherent
cells removed by washing the biofilms with sterile ultra-
pure water [11].
Extraction of the Antifungal Agent from Biofilms
After biofilm formation in the presence of the
antifungal agent, each well of the 24-well plate was
treated as one single biofilm microecosystem. A
diagram summarizing the protocol steps is presented
in Fig. 1. Firstly, the supernatant from the biofilms
was collected (volume = 350 lL), centrifuged at
12,000g during 10 min, and filtered with a 0.22-lm
filter to remove possible contaminant cells (superna-
tant fraction). In parallel, the biofilm remaining in the
wells was scrapped with 150 lL of sterile water and
the suspension was collected, sonicated (Ultrasonic
Processor, Cole Parmer) during 10 s at 30 %, and
centrifuged at 12,000g during 10 min [11]. Finally, the
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resultant supernatant was filtered with a 0.22-lm filter
to remove cells (matrix). Sonication time was opti-
mized for this procedure, making colonies formation
units counts as controls. The samples were stored at
-20 C until the detection, and quantification method
was executed. Each assay was performed with six
samples, in three independent assays.
The high-pressure liquid chromatography (HPLC—
Varian 9002/Pro-Star) method was performed using a
C18 column (YMC, Inc). For that, a slightly modified
method from Sadasivudu et al. [12] was performed. The
mobile phase was acetonitrile:water (50:50) (Fisher
Chemicals) with a flow of 1 mL/min, during 6 min for
each sample, read at 260 nm. Standards of Flu used for
the calibration curve were prepared with the mobile
phase in the following range: 1.0, 2.0, 4.0, 8.0, 20.0,
40.0, and 100.0 mg/L. The obtained equation was
Area = (0.091 9 [Flu]) ? 0.007, r2 = 0.996.
Results and Discussion
In the last years, biofilms are gaining much more
importance not only in the research field, but also on the
clinical practice. As it is known, they confer significant
resistance to antifungal therapy, by limiting the pene-
tration of the xenobiotic through the matrix, thus
protecting cells [2, 9, 14]. However, the knowledge on
this ground is still scarce, especially in Candida
biofilms. The fact that biofilms are very complex
structures, due to their environment and matrix, make
the studies more difficult to execute. Also, it is known
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Fig. 1 Scheme of the
method for detection and
quantification of fluconazole
within Candida biofilms
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that antifungal agents’ action in biofilms is poor, and
one of the main responsible for that inactivity the
extracellular matrix [14]. The mechanisms involved in
this phenomena and the pathway taken by the anti-
fungal compounds or the amount of drug that reaches
the cells, crossing the biofilm matrix, are still unknown
[14–16]. So, it is of major importance to verify if the
antifungal agents are still in the biofilm environment
(supernatant fraction) or if they are retained in the
extracellular matrix (matrix fraction).
Therefore, the aim of this work was to detect and
quantify the presence of the Flu on C. glabrata’s
biofilms, after its isolation from supernatants and
matrices (Fig. 1). The HPLC methodology proposed
by Sadasivudu et al. was slightly modified in order to
quantify this drug, recovered from both fractions. As
observed in Fig. 2, Flu was easily detected in C.
glabrata’s biofilm fractions and presented a peak at the
retention time of 3.5 min, at 260 nm. In addition, the
calibration curve obtained (Area = 0.091 [Flu] ?
0.007) and confirmed that HPLC is a goodmethodology
to detect Flu, with a correlation factor of 0.996. The
Fig. 2 Chromatograms of the detection and quantification of
fluconazole within C. glabrata’s biofilms. a Control 0 mg/L;
b fluconazole’s standard 40 mg/L; c C. glabrata 562123 matrix;
d C. glabrata 562123 supernatant; e C. glabrata 534784 matrix;
f C. glabrata 534784 supernatant
Table 1 Quantification of fluconazole (Flu) present in C.
glabrata strains biofilm supernatant (S) and matrix
(M) fractions
Biofilm strains Average [Flu] mg/L ± SD
C. glabrata 562123 S 551.96 ± 44.22
M 60.81 ± 1.43
C. glabrata 534784 S 707.29 ± 34.97
M 67.96 ± 2.54
SD standard deviation
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detection of Flu, present in biofilm supernatants
(Fig. 2d–f) and in their matrices (Fig. 2c–e), was
obtained without any interference, presenting a clear
peakwith the same retention time. In order to confirm the
reliability of the methodology, two biofilms of C.
glabrata strains were assessed, since they showed
significant different biofilm susceptibilities profiles to
Flu (P\0.0001): C. glabrata’s 562123 biofilm is more
susceptible (20 % of biofilm biomass inhibition, using
Crystal Violet assay [13]) than C. glabrata’s 534784
biofilm(with13 %of inhibition, fromcrystal violet assay
[13]). The quantification of Flu present on both biofilm
supernatants and matrices is presented in Table 1.
Interestingly, in samples of C. glabrata 562123,
which is the less resistant, we noticed a lower amount
of Flu in both fractions, which means that it is likely
that there was a higher proportion of the antifungal
reaching the cells and, consequently, causing the
greater inhibition. In opposition, C. glabrata 534784
had a high amount of antifungal in the medium,
probably showing the capacity of the strain to avoid
the antifungal entering in its cells. It is important to
address that the method optimized, has the advantage
of detecting low quantities of the drug, is easy and low
time-consuming. Additionally, this methodology can
also be used to study of the dynamic of interaction of
other compounds (e.g., hormones, nutrients, and other
chemical compounds) within the biofilm matrices of
any other microorganism (yeast and bacteria).
In summary, we are proposing a methodology that
will allow a better understanding of biofilms and
drugs, regarding the amount of a compound present in
the supernatant of matrices of biofilm, which will be
an important step to understand the problematic of
biofilm resistance and the higher number of diseases
associated with them.
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